期刊文献+

人乳头瘤病毒检测联合TCT检测宫颈病变 被引量:9

Significance of Joint Screening of Cervical Lesions with HPV Test and TCT
暂未订购
导出
摘要 目的比较液基薄层细胞学检查(TCT)联合人乳头瘤病毒(HPV)与单纯TCT检测在筛查宫颈病变中的意义。方法分析2010年2月-2012年2月在妇瘤科完成宫颈HPV检测联合TCT检查的患者523例,对326例宫颈TCT检查阳性患者行阴道镜检查,依据病理结果分析符合率。结果 ASCUS 24例,LSIL 226例,HSIL 76例,同时接受HPV检测阳性率分别为41.7%(10/24),69.0%(156/226),90.8%(69/76)。ASCUS组的HPV感染阳性率与LSIL、HSIL差异均有统计学意义(P<0.05)。TCT阳性326人,病检阳性225人,符合率69.02%,TCT及HPV均阳性235人,病检阳性232人,阳性符合率为98.72%。随病理级别升高,HPV和TCT均阳性检出率也越来越高。两组与病理检查符合率比较,差异有统计学意义(P<0.05)。结论 HPV检测联合TCT为减少宫颈高级别病变漏诊最有效的方法,用于宫颈癌筛查,有效防治宫颈病变。 Objective To explore the significance of the joint TCT and HPV testing in screening cervical lesions.Methods From February 2011 to February 2012,523 cases in our hospital were performed cervical HPV and TCT test,326 cases of cervical TCT check with positive were examined with vaginal endoscopy,the analysis was conducted based on pathology results logging.Results ASCUS 22 cases,LSIL 226 cases,HSIL 76 cases,HPV positive rate were 45.5%(10/22),69.0%(156/226),90.8%(69/76).ASCUS group of HPV infection with positive LSIL,HSIL were significant difference(P0.05).326 people were TCT positive,225 people sick for positive,coincidence rate was 69.02%,TCT and HPV were positive among 235 people,232 positive people was sick,positive was 98.72%.With the increased level of pathology,HPV and TCT positive detection rate were more and more high.The difference was statistically significant(P0.05) between pure TCT and joint screening.Conclusion Joint testing can reduce misdiagnosis,which was the most effective way,it can be used for cervical cancer screening,it was effective way to prevent and cure cervical lesions.
出处 《中华全科医学》 2013年第3期383-384,共2页 Chinese Journal of General Practice
关键词 人乳头瘤状病毒 液基细胞学检查 宫颈高级别病变 Human papilloma virus Thin Prep Cytologic Test Cervical high level lesions
  • 相关文献

参考文献10

二级参考文献113

  • 1苏佳斌,闵军霞,梅冠廷.子宫颈癌患者的人格特征研究[J].解放军护理杂志,2000,17(6):14-15. 被引量:6
  • 2周琦.子宫颈癌与人乳头状瘤病毒感染[J].肿瘤学杂志,2005,11(2):81-82. 被引量:7
  • 3谢立辉,陈克力.中西医结合治疗复发性尖锐湿疣86例[J].实用中医药杂志,2005,21(9):549-549. 被引量:2
  • 4Smith J S, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions:A metaanalysis update[ J]. Int J Cancer,2007,121 (3) : 621-632.
  • 5Wright T C. Cervicalcaneer screening in the 21st century :Is it time to retire the PAP smear [ J ] .9 Clin Obstet Gynecol, 2007,50 ( 2 ) : 313 -323.
  • 6Cuzick J, Clavel C, Petry K U, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening [ J ]. Int J Cacer,2006,119 (4) : 1095 -1101.
  • 7Castle P E, Sided M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer [ J ]. Am J Obstet Gynecol, 2007, 197(2) :351-356.
  • 8Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries [ J ]. Vaccine,2008,26(10) :K29-K41.
  • 9Thomas C, Jr W L, Massad S, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests [ J ]. American Society for Colposcopy and Cervical Pat hology Journal of Lower Genital Tract Disease,2007,11 ( 2 ) : 201-222.
  • 10Castle P E, Cox J T, Schiffman M, et al. Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology [ J ]. Obstet Gynecol,2008,112 ( 3 ) :637-645.

共引文献1153

同被引文献104

引证文献9

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部